BridgeBio Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for BridgeBio Oncology (BBOT).

Price Target Range — 6 Quarters

Analyst Consensus — 9 Analysts

9Buy

Consensus RatingOutperform# Analysts9Avg. Consensus PT$21Upside to Avg. PT+709.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	Morgan Stanley	Sean Laaman	PT Cut	Overweight	$18→$13
Oct 20, 2026	Oppenheimer	Mazahir Alimohamed	PT Cut	Outperform	$22→$16
Sep 11, 2026	JP Morgan	Priyanka Grover	PT Cut	Overweight	$25→$23
Sep 10, 2026	Leerink Partners	Andrew Berens	PT Cut	Outperform	$39→$27
Sep 9, 2026	Canaccord Genuity	John Newman	PT Cut	Buy	$23→$20
Sep 9, 2026	Raymond James	Sean McCutcheon	PT Cut	Outperform	$24→$22
Sep 9, 2026	Stifel	Laura Prendergast	PT Cut	Buy	$23→$15
Sep 9, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$25
Aug 14, 2026	JP Morgan	Priyanka Grover	PT Cut	Overweight	$27→$25
Jul 8, 2026	JP Morgan	Priyanka Grover	Initiate	Overweight	$27
Jun 22, 2026	Oppenheimer	Mazahir Alimohamed	Assumes	Outperform	$22
May 11, 2026	Canaccord Genuity	John Newman	Initiate	Buy	$23
Mar 6, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$27→$29
Feb 11, 2026	Stifel	Laura Prendergast	Initiate	Buy	$23
Jan 9, 2026	Raymond James	Sean McCutcheon	Initiate	Outperform	$24
Dec 11, 2025	Wedbush	David Nierengarten	Maintained	Outperform	$25
Dec 5, 2025	Morgan Stanley	Sean Laaman	Initiate	Overweight	$20
Nov 25, 2025	Wedbush	David Nierengarten	Maintained	Outperform	$25
Nov 13, 2025	Oppenheimer	Matthew Biegler	PT Cut	Outperform	$23→$22
Sep 17, 2025	Leerink Partners	Andrew Berens	Initiate	Outperform	$25

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13

Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $18 to $13.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16

Oppenheimer analyst Mazahir Alimohamed maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $22 to $16.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27

Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20

Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $20.

Benzinga Newsdesk

PRO
Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22

Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15

Stifel analyst Laura Prendergast maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $15.

Benzinga Newsdesk

BridgeBio Oncology Therapeutics Inc

BridgeBio Oncology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13

PRO
Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16

PRO
Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27

PRO
Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20

PRO
Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22

PRO
Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15

People Also Watch

People Also Watch

BridgeBio Oncology Therapeutics Inc

BridgeBio Oncology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13

PROOppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16

PROLeerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27

PROCanaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20

PRORaymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22

PROStifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13

PRO
Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16

PRO
Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27

PRO
Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20

PRO
Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22

PRO
Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15